KRAS, BRAF, PIK3CA Array Targeted mutation profiling

KRAS, BRAF, PIK3CA* Array Rapid profiling of point mutations in the KRAS, BRAF and PIK3CA genes Introduction Colorectal cancer (CRC) is the third most common cancer worldwide.1 Metastatic disease accounts for 4050% of newly diagnosed patients and is associated with high morbidity.1,2 Despite recent therapeutic advances, the prognosis for patients with metastatic CRC (mCRC) remains poor.3 In recent years monoclonal antibodies (moAbs), like cetuximab and panitumumab which target the epidermal growth factor receptor (EGFR), have proven to be effective in combination with chemotherapy or as single...

Why test the KRAS, BRAF, and PIK3CA genes? Early studies conducted on mainly heavily pre-treated chemotherapy-refractory patients and also chemotherapynaive patients with mCRC indicated that only 10-20% of patients clinically benefited from anti-EGFR moAbs.5,6 Consequently oncogenic activation of EGFR downstream effectors was investigated with respect to clinical outcome to moAb therapy. Analysis confirmed that patients with mCRC carrying activating KRAS gene mutations do not benefit from anti-EGFR moAb therapy.7,8 KRAS mutations have since emerged as the major negative predictor of efficacy...

Evidence Investigator Multiplexing...proven, perfected, evolved The Evidence Investigator is a semi-automated, benchtop biochip analyser which offers complete patient profiling. Save time and costs Multiplexing reduces time, labour and reagents associated with multiple individual tests Increase throughput For greater laboratory efficiency Consolidation Of immunoassays and molecular diagnostics, improving laboratory efficiency Result traceability Chain of custody features and bar coded reagents No hidden costs Package includes imaging module, PC and imaging software, thermoshaker, biochip carrier...